ArticleJournal of clinical hypertension (Greenwich, Conn.)2025
Hypertension Prevalence, Awareness, and Control in US Adults Before and After the COVID-19 Pandemic.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Risk of infection in ocrelizumab-treated adults with multiple sclerosis aged 55 years and older: a retrospective cohort study.Lancet regional health. Americas · 2026Article
- Catheter-Based Renal Denervation in Uncontrolled and Resistant Hypertension: Evidence, Guidelines, Special Populations and Clinical Implementation.Journal of cardiovascular development and disease · 2026Review
- Artificial Intelligence-Driven Hypertension Management: Implications for Quality Improvement and Prevention of End-Organ Damage.Life (Basel, Switzerland) · 2026Review
- Increased Cervical Disc Height and Decreased Neck Pain and Disability Following Improvement in Cervical Lordosis and Posture Using Chiropractic BioPhysics.Bioengineering (Basel, Switzerland) · 2026Article
- Implications of the 2025 AHA/ACC hypertension guideline on hypertension prevalence, treatment eligibility and blood pressure control in Nigeria: a cross-sectional comparative study.BMJ public health · 2026Article
- Disease-specific drivers of sex- and locality-related disparities in life expectancy at age 65: two decades of progress before COVID-19.Innovation in aging · 2026Article
- Hypertension among Middle Eastern and North African adults residing in the United States: addressing equity in health research representation using the All of Us Research Program, 2000-2024.Frontiers in medicine · 2026Article
- Zilebesiran as an Innovative siRNA-Based Therapeutic Approach for Hypertension: Emerging Perspectives in Cardiovascular Medicine.International journal of molecular sciences · 2025Review
- Lessons Learned From COVID-19: Never Lower the Guard in Promoting Hypertension Awareness.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is a leading cause of death and disability in the United States, but national trends in hypertension after the COVID-19 pandemic remain unknown. We analyzed NHANES data from pre-pandemic (2017-March 2020) and post-pandemic (August 2021-August 2023) surveys to determine nationwide prevalence, awareness, and control of hypertension. Weighted, age-standardized prevalence estimates were compared using Poisson regression with prevalence ratios (PRs). Among 14 449 participants representing 237 million US adults, hypertension prevalence was 49.5% pre-pandemic versus 47.7% post-pandemic (PR 0.96; p = 0.15). Overall, hypertension awareness was unchanged (57.7% vs. 53.7%; PR 0.96; p = 0.14) but declined among adults aged 18-39 years (PR 0.78; p = 0.02). Blood pressure control remained low (25.9% vs. 22.3%; PR 0.91; p = 0.06) and worsened in men (PR 0.83; p = 0.01). In conclusion, hypertension prevalence, awareness, and control did not significantly improve post-pandemic. More aggressive public health efforts are needed to reduce the adverse impacts of hypertension in the United States.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.